ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1909

High-density Proteomic Analysis of Skin Blister Fluid and Plasma in Systemic Sclerosis Identifies Local and Systemic Differences for Key Proteins

Kristina Clark1, Corrado Campochiaro2, Eszter Csomor3, Adam Taylor3, Katherine Nevin3, Mary Morse3, Voon Ong4, Emma Derrett-Smith5, Nicolas Wisniacki3, Shaun Flint3 and Christopher Denton1, 1University College London, London, United Kingdom, 2Royal Free Hospital NHS trust, London, United Kingdom, 3GlaxoSmithKline, Stevenage, United Kingdom, 4UCL, London, United Kingdom, 5University College London Division of Medicine, London, United Kingdom

Meeting: ACR Convergence 2020

Keywords: proteomics, Scleroderma, Systemic, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Systemic Sclerosis & Related Disorders – Basic Science Poster

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Simultaneous analysis of multiple proteins in biological fluids offers insight into the pathogenesis of SSc. Here, we report a proteomic analysis of plasma and dermal interstitial fluid in SSc compared with healthy controls (HC).

Methods: The prospectively collected BIOPSY cohort recruited 52 SSc patients (21 early dcSSc, 15 established dcSSc, 16 lcSSc) and 16 matched HC. 36 (69%) of the SSc patients are female. Mean baseline skin score (MRSS) for early dcSSc was 21 (sd 11.2). This analysis utilised forearm skin blister fluid obtained using the dermal suction blister method and paired simultaneous plasma samples from early dcSSc and HC at baseline. These were assayed using the Olink antibody platform with proximity extension assay (www.olink.com) and reported as normalized protein expression (NPX), corresponding to log2 (expression). T-test with FDR correction (p< 0.05) assessed statistical significance. Pathway analysis was conducted by STRING consortium 2020.

Results: 1196 proteins were analysed in paired blister/plasma samples from 14 early dcSSc patients and 16 HC. 447 proteins were significantly different in the blister fluid of early dcSSc patients compared with HC (see Table 1), whereas in plasma this was only 183 proteins. Of these, 130 proteins were simultaneously different in both blister fluid and plasma of early dcSSc including key cytokines associated with fibrosis and vasculopathy such as IL-6, VEGF-1, MCP-1, COL4A1, COMP, Thy1 and THBS4. No correlation was seen between any of these proteins and MRSS.

There were 310 proteins significantly elevated in blister fluid alone in early dcSSc patients compared to HC. These included cytokines (IL7, IL18, OSM), chemokines (CCL7, CCL18, CCL3), matricellular proteins (CYR61 and osteopontin). Pathway analysis using all significantly elevated proteins in blister fluid in early dcSSc compared to HV identified the top GO biological processes as immune system, response to stimulus, immune response and cell communication (FDR< 0.01). KEGG pathway analysis highlighted cytokine-cytokine receptor interaction, cell adhesion molecules, MAPK signalling pathway and the PI3K-AKT signalling pathway (FDR< 0.01).

Conclusion: Numerous dysregulated proteins were identified in dermal blister fluid and plasma of early dcSSc patients. Substantially more were identified in dermal blister fluid, highlighting the potential of this technique for providing detailed information on local pathologic processes. A subset of proteins were dysregulated in both plasma and blister fluid, suggesting these may reflect systemic abnormalities. Further work will utilise this cohort to integrate gene and protein expression across the full spectrum of early dcSSc, established dcSSc and lcSSc.

Table 1: Top 20 most upregulated proteins in skin blister fluid for early dcSSc (n=14) compared with healthy control (HC, n=16)


Disclosure: K. Clark, None; C. Campochiaro, None; E. Csomor, GlaxoSmithKline, 3; A. Taylor, GlaxoSmithKline, 3; K. Nevin, GlaxoSmithKline, 3; M. Morse, GlaxoSmithKline, 3; V. Ong, None; E. Derrett-Smith, None; N. Wisniacki, GlaxoSmithKline, 3; S. Flint, GlaxoSmithKline, 3; C. Denton, Janssen, 1, GlaxoSmithKline, 1, 2, Bayer, 1, Sanofi, 1, Inventiva, 1, 2, Boehringer Ingelheim, 1, Roche, 1, Bristol-Myers Squibb, 1, CSL Behring, 1, 2, UCB, 1, Leadiant Biosciences, 1, Corbus Pharmaceuticals, 1, Acceleron Pharma, 1, Horizon Therapeutics, 1, Forbius, 1, Servier, 1.

To cite this abstract in AMA style:

Clark K, Campochiaro C, Csomor E, Taylor A, Nevin K, Morse M, Ong V, Derrett-Smith E, Wisniacki N, Flint S, Denton C. High-density Proteomic Analysis of Skin Blister Fluid and Plasma in Systemic Sclerosis Identifies Local and Systemic Differences for Key Proteins [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/high-density-proteomic-analysis-of-skin-blister-fluid-and-plasma-in-systemic-sclerosis-identifies-local-and-systemic-differences-for-key-proteins/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/high-density-proteomic-analysis-of-skin-blister-fluid-and-plasma-in-systemic-sclerosis-identifies-local-and-systemic-differences-for-key-proteins/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology